Prophylaxis linked to improved function, HRQoL in hemophilia

August 31, 2017

(HealthDay)—For adults with severe hemophilia and pre-existing joint disease, prophylaxis is associated with improved function, quality of life, activity, and pain, according to a study published online Aug. 24 in the Journal of Thrombosis and Haemostasis.

Marilyn J. Manco-Johnson, M.D., from the University of Colorado Anschutz Medical Campus in Aurora, and colleagues described three-year bleeding, joint function, health-related quality-of-life (HRQoL), and other outcomes for males aged 12 to 50 years with severe hemophilia who were randomized to sucrose-formulated recombinant FVIII prophylaxis or on-demand (OD) therapy.

The researchers found that maintained excellent adherence following three years of prophylaxis, with 94 percent reduction in total and joint bleeding events (BEs) despite severe pre-existing arthropathy. Overall, 35.7 percent of prophylaxis participants were bleed-free and 76.2 percent had fewer than two BEs per year. Prophylaxis correlated with improved joint health, as assessed by the Colorado Adult Joint Assessment Scale, compared with OD, and with improved HAEMO-QoL-A scores, less chronic pain, and about twofold less health care resource utilization (HRU). Prophylaxis was also favored in activity, EQ-5D-3L, and satisfaction scores. There was no difference in score changes for prophylaxis versus OD.

"Prophylaxis versus OD in adults with severe hemophilia A and arthropathy led to decreased bleeding, pain, and HRU, better joint health, activity, satisfaction, and HRQoL, but no reduction in structural arthropathy progression, suggesting preexisting joint arthropathy may be irreversible," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Bayer AG, which funded the study.

Explore further: Improved survival with enhanced prophylaxis plus ART in HIV

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Improved survival with enhanced prophylaxis plus ART in HIV

July 20, 2017
(HealthDay)—For patients with advanced HIV who are initiating antiretroviral therapy (ART), enhanced prophylaxis is associated with reduced rates of death at 24 and 48 weeks, according to a study published in the July 20 ...

Preventive hemophilia A treatment reduces annual bleeding events and frequency of infusions

January 9, 2012
A Rush University Medical Center led international research team has announced that a treatment to prevent bleeding episodes in children with hemophilia A also is effective for adolescents and adults.

Meta-analysis: caprini score IDs benefit of VTE prophylaxis

January 26, 2017
(HealthDay)—Perioperative venous thromboembolism (VTE) prophylaxis is beneficial only for surgical patients with Caprini scores of ≥7, according to a meta-analysis published online Jan. 23 in the Annals of Surgery.

Approaches compared for aspirin prophylaxis for preeclampsia

November 17, 2015
(HealthDay)—The best approaches to low-dose aspirin prophylaxis for the prevention of preeclampsia seem to be the U.S. Preventive Services Task Force (USPSTF) recommendations and universal prophylaxis, according to a study ...

AAPM: Platelet-rich plasma offers short-term benefit

March 31, 2015
(HealthDay)—For patients with facet joint arthropathy, platelet-rich plasma (PRP) has a short-term positive impact, according to a study presented at the annual meeting of the American Academy of Pain Medicine, held from ...

After hip replacement, aspirin cost-effective for VTE prophylaxis

August 1, 2013
(HealthDay)—Aspirin is a cost-effective choice for prophylaxis of venous thromboembolism (VTE) following total hip arthroplasty, but the choice of aspirin versus low-molecular-weight heparin (LMWH) for patients younger ...

Recommended for you

Screening could catch a quarter of hip fractures before they happen

December 15, 2017
Community screening for osteoporosis could prevent more than a quarter of hip fractures in older women - according to new research led by the University of East Anglia (UEA).

New cellular approach found to control progression of chronic kidney disease

December 15, 2017
Researchers have demonstrated for the first time that extracellular vesicles - tiny protein-filled structures - isolated from amniotic fluid stem cells (AFSCs) can be used to effectively slow the progression of kidney damage ...

Testing shows differences in efficacy of Zika vaccines after one year

December 15, 2017
(Medical Xpress)—A large team of researchers with members from Harvard Medical School, Walter Reed Army Institute of Research, Bioqual Inc. and MIT has found that the efficacy of the three types of Zika vaccines currently ...

How to regulate fecal microbiota transplants

December 15, 2017
(Medical Xpress)—A small team of researchers at the University of Maryland, some with affiliations to the Veterans Affairs Maryland Health Care System, has written and published a Policy Forum piece in the journal Science ...

Urine test developed to test for tuberculosis

December 14, 2017
(Medical Xpress)—An international team of researchers has developed a urine test that can be used to detect tuberculosis (TB) in human patients. In their paper published in Science Translational Medicine, the group describes ...

40 years after first Ebola outbreak, survivors show signs they can stave off new infection

December 14, 2017
Survivors of the first known Ebola outbreak, which occurred in the Democratic Republic of the Congo in 1976, may be key to development of vaccines and therapeutic drugs to treat future outbreaks, according to a new study ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.